Revolutionizing Alzheimer's Disease Treatment: The Role of Novel Drug Delivery Systems and Artificial Intelligence

2025

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.64149/j.carcinog.24.7s.414-431
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Alzheimer's disease is a multifaceted neurodegenerative disorder with no definitive cure, posing significant challenges in treatment. Recent advancements in drug delivery systems, particularly through nanotechnology, and the integration of artificial intelligence and machine learning, have offered promising new avenues for enhancing AD management. Nanoparticle-based drug delivery systems are being utilized to improve the targeting and bioavailability of therapeutic agents, allowing more efficient crossing of the blood-brain barrier. Concurrently, AI-driven approaches are being employed to facilitate early diagnosis, optimize treatment strategies, and predict patient outcomes by analyzing complex datasets, including brain imaging and biomarker data. Also, a multidrug, multi-target treatment approach, similar to chemotherapy, is emerging as a potential strategy for addressing the complexity of AD. This review discusses the various AI and nanotechnology-driven innovations in AD, the current challenges in treatment, and the future directions for research. Continued exploration of these technologies, combined with early detection, lifestyle interventions, and precision medicine, holds the potential to revolutionize AD care, minimizing disease recurrence and enhancing patient quality of life.